Literature DB >> 16635084

Expression of peroxiredoxin and thioredoxin in human lung cancer and paired normal lung.

Joo Hun Park1, Young Sun Kim, Hye Lim Lee, Jin Young Shim, Keu Sung Lee, Yoon Jung Oh, Seung Soo Shin, Young Hwa Choi, Kwang Joo Park, Rae Woong Park, Sung Chul Hwang.   

Abstract

BACKGROUND: Peroxiredoxins (Prxs) have been implicated in regulating many cellular processes including cell proliferation, differentiation and apoptosis. However, the pathophysiological significance of Prx proteins, especially in lung disease, has not been defined. Therefore, the authors investigated the distribution and expression of various Prx isoforms in lung cancer and compared this with normal lung from human and mouse.
METHODS: Patients diagnosed with lung cancer who underwent surgery at Ajou Medical Center were enrolled. Expression of Prxs, thioredoxin and thioredoxin reductase was analysed by proteomic techniques. Immunohistochemistry was performed to localize Prx proteins.
RESULTS: Immunohistochemical staining showed that the isoforms of Prx I, II, III and V were predominantly expressed in bronchial and alveolar epithelium as well as in alveolar macrophages of the normal mouse lung. The isoforms I, III and thioredoxin were overexpressed in lung cancer tissues compared with normal lungs. There was also an increased amount of oxidized form of Prx I and a putative truncated form of Prx III in lung cancer samples when analysed on two-dimensional electrophoresis. In addition, a 40-kDa intermediate MW protein band and high MW bands of over 20 kDa, recognized by anti-Prx (a-Prx) I antibody, were present in tissue extracts of lung cancer patients on one-dimensional electrophoresis.
CONCLUSION: The upregulation of Prx I, Prx III and thioredoxin in lung cancer tissue may represent an attempt by tumour cells to adjust to the microenvironment in a manner that is advantageous to survival and proliferation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16635084     DOI: 10.1111/j.1440-1843.2006.00849.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  38 in total

1.  Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study.

Authors:  Francesca Magherini; Alessandra Modesti; Luca Bini; Michele Puglia; Ida Landini; Stefania Nobili; Enrico Mini; Maria Agostina Cinellu; Chiara Gabbiani; Luigi Messori
Journal:  J Biol Inorg Chem       Date:  2010-01-29       Impact factor: 3.358

Review 2.  The functional role of peroxiredoxin 3 in reactive oxygen species, apoptosis, and chemoresistance of cancer cells.

Authors:  Lianqin Li; Ai-Qun Yu
Journal:  J Cancer Res Clin Oncol       Date:  2015-01-21       Impact factor: 4.553

3.  Identification of isocitrate dehydrogenase 1 as a potential diagnostic and prognostic biomarker for non-small cell lung cancer by proteomic analysis.

Authors:  Fengwei Tan; Ying Jiang; Nan Sun; Zhaoli Chen; Yongzhuang Lv; Kang Shao; Ning Li; Bin Qiu; Yibo Gao; Baozhong Li; Xiaogang Tan; Fang Zhou; Zhen Wang; Dapeng Ding; Jiwen Wang; Jian Sun; Jie Hang; Susheng Shi; Xiaoli Feng; Fuchu He; Jie He
Journal:  Mol Cell Proteomics       Date:  2011-11-07       Impact factor: 5.911

4.  Differential expression of peroxiredoxins in prostate cancer: consistent upregulation of PRDX3 and PRDX4.

Authors:  Anamika Basu; Hiya Banerjee; Heather Rojas; Shannalee R Martinez; Sourav Roy; Zhenyu Jia; Michael B Lilly; Marino De León; Carlos A Casiano
Journal:  Prostate       Date:  2010-10-28       Impact factor: 4.104

5.  Inhibition of TRAF6 ubiquitin-ligase activity by PRDX1 leads to inhibition of NFKB activation and autophagy activation.

Authors:  Yoon Min; Mi-Jeong Kim; Sena Lee; Eunyoung Chun; Ki-Young Lee
Journal:  Autophagy       Date:  2018-07-23       Impact factor: 16.016

6.  Expression of peroxiredoxin 1 and 4 promotes human lung cancer malignancy.

Authors:  Hong Jiang; Lisha Wu; Murli Mishra; Hedy A Chawsheen; Qiou Wei
Journal:  Am J Cancer Res       Date:  2014-09-06       Impact factor: 6.166

Review 7.  Proteomic biomarkers in lung cancer.

Authors:  M D Pastor; A Nogal; S Molina-Pinelo; A Carnero; L Paz-Ares
Journal:  Clin Transl Oncol       Date:  2013-04-20       Impact factor: 3.405

Review 8.  Peroxiredoxins, gerontogenes linking aging to genome instability and cancer.

Authors:  Thomas Nyström; Junsheng Yang; Mikael Molin
Journal:  Genes Dev       Date:  2012-09-15       Impact factor: 11.361

9.  Peroxiredoxin 3 is resistant to oxidation-induced apoptosis of Hep-3b cells.

Authors:  Y-G Wang; L Li; C-H Liu; S Hong; M-J Zhang
Journal:  Clin Transl Oncol       Date:  2013-10-09       Impact factor: 3.405

10.  Selectively decreased expression of peroxiredoxins induced by silica in pulmonary epithelial cells.

Authors:  Hye Lim Lee; Young Sun Kim; Joo Hun Park; Wou Young Chung; Kyu Sung Lee; Yoon Jung Oh; Seung Soo Sheen; Kwang Joo Park; Sung Chul Hwang
Journal:  Korean J Intern Med       Date:  2009-08-26       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.